Philadelphia is a top-tier life sciences hub, in large part because of the greater area’s biotech presence, grade-A universities, and more than $1 billion in NIH funding for research organizations. All that has led to a dynamic entrepreneurial culture: Venture capital for life-science startups almost quintupled last year.
But the city faces steep competition, especially from stops along the Acela corridor -- Boston, New York, and Washington. Can Philadelphia keep up?
The Atlantic will convene community leaders from the health care and biotech industries to discuss how Philadelphia can become an unstoppable engine of the life-sciences industry.